ADMA Biologics Receives Milestone Payment From Biotest AG for RI-002 BLA Submission to FDA
GlobeNewswire - Wed Sep 30, 6:28AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced it has received a milestone payment from Biotest Aktiengesellschaft (Biotest AG) as a result of the filing of its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA), in accordance with the license agreement entered into on December 31, 2012.
ADMA: 9.37 (+0.12)
ADMA Biologics Recognized as One of the 50 Fastest Growing Companies in New Jersey
GlobeNewswire - Mon Sep 28, 6:28AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced today that the Company has been recognized as one of the 50 fastest growing companies in New Jersey by NJBIZ, a leading New Jersey-focused weekly business new publication.
ADMA: 9.37 (+0.12)
ADMA Biologics to Present at the Ladenburg Thalmann 2015 Healthcare Conference
GlobeNewswire - Tue Sep 22, 7:28AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it will present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015 in New York City at the Sofitel New York.
ADMA: 9.37 (+0.12)
Global Diagnostics Partnering 2010-2015: Deal Trends, Players, Financials and Forecasts for 150+ Companies
M2 - Tue Sep 22, 6:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hm3w3j/global) has announced the addition of the "Global Diagnostics Partnering 2010-2015: Deal trends, players, financials and forecasts" report to their offering. The Global Diagnostics Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering: - Companion Diagnostics - Imaging - CT - Endoscope - Molecular and nuclear - MRI - Ultrasound - X-ray - PET - SPECT - Angiography - Fluroscopy - Mammography - In vitro diagnostics - Molecular diagnostics - Prognostics - Theranostics Report scope: Global Diagnostics Partnering 2010-2015 is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide. Global Diagnostics Partnering 2010-2015 includes: - Trends in diagnostic dealmaking in the biopharma industry since 2010 - Analysis of diagnostic deal structure - Case studies of real-life diagnostic deals - Access to over 3,000 diagnostic deals - The leading diagnostic deals by value since 2010 - Most active diagnostic dealmakers since 2010 - The leading diagnostic partnering resources In Global Diagnostics Partnering 2010-2015 , the available contracts are listed by: - Headline value - Stage of development at signing - Deal component type - Specific therapy target Companies Mentioned - Partial List - Abaxis - Abbott Laboratories - Accuray - Achaogen - Actavis (acquired by Watson) - Acusphere - ADMA Biologics - Aegea Biotechnologies - Alnylam Pharmaceuticals - Alseres Pharmaceuticals - Altair Nanotechnologies - Amarantus BioSciences - Ambit Biosciences - AMDL Diagnostics - AmpliPhi Biosciences - Amway Global - ARK Diagnostics - Arno Therapeutics - Arrayit - Arrayit Diagnostics - AspenBio Pharma - Asuragen - Atossa Genetics - Audeo Oncology - Axial Biotech - Bayer Schering Pharma - Beckman Coulter - Beijing C&D - BG Medicine - Bio-Imaging Technologies - Bio-Matrix Scientific - Biocept - BioClinica - Biofield - Biogen Idec For more information visit http://www.researchandmarkets.com/research/hm3w3j/global
BIIB: 269.16 (-10.72), ABT: 41.89 (+0.73), ADMA: 9.37 (+0.12), APPY: 0.32 (-0.01), APHB: 6.51 (+0.78), ATOS: 0.77 (+0.01), ABAX: 46.25 (+1.44)
FDA Accepts ADMA Biologics License Application for RI-002
GlobeNewswire - Mon Sep 21, 6:28AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for RI-002 intended for the primary immunodeficiency (PI) population. PI is a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system due to either a lack of necessary antibodies or a failure of these antibodies to function properly, affecting approximately 250,000 people in the United States.
ADMA: 9.37 (+0.12)
ADMA Biologics wins US FDA approval for second plasma collection centre in Marietta, Georgia
M2 - Fri Sep 18, 3:29AM CDT
Biopharmaceutical company ADMA Biologics (NasdaqCM:ADMA) reported on Thursday that it has been given US Food and Drug Administration (FDA) approval to sell human source plasma from its second plasma centre within the US.
ADMA: 9.37 (+0.12)
ADMA Biologics Receives FDA Approval for Second Plasma Collection Center
GlobeNewswire - Thu Sep 17, 6:38AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics, announced that the Company's second plasma center, located at 3000 Windy Hill Road in Marietta, Georgia has received U.S. Food and Drug Administration (FDA) approval to sell human source plasma within the U.S. This center measures over 10,000 square feet, has the potential to support over 50 donor beds and employ over 50 staff members at peak capacity. Plasma donors donating at an ADMA BioCenter may be paid as much as $300 per month.
ADMA: 9.37 (+0.12)
Global Plasma Therapeutics Market 2015-2019
M2 - Wed Sep 09, 8:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/skzsk3/global_plasma) has announced the addition of the "Global Plasma Therapeutics Market 2015-2019" report to their offering. The global plasma therapeutics market to grow at a CAGR of 12.10% over the period 2014-2019. The report covers the present scenario and the growth prospects of the global plasma therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded therapies derived from the various fractions of plasma such as albumin, immunoglobulins, coagulation factors, hyperimmune globulins, and A1PI. The report, Global Plasma Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global plasma therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. Patient assistance programs for plasma therapeutics are boosting the growth of the market. Vendors nowadays provide co-pay assistance to individuals who purchase plasma therapeutics. According to the report, IVIG is the largest segment of the plasma therapeutics market. IVIG is being increasingly used due to increases in the number of bleeding disorders, CIDP, and the global aging population. This has led to increased demand for IVIG therapeutics. Further, the report states that the high cost of plasma therapeutics hinders market growth. Plasma protein therapies cost nearly four times more than other pharmaceutical medicines because of the use of expensive technologies in the manufacturing and processing of plasma-derived products. Key vendors - Baxter - CSL Behring - Grifols Therapeutics - Octapharma Other prominent vendors - Abeona Therapeutics - ADMA Biologics - Amag Pharmaceuticals - Antares Pharma - BioDelivery Sciences - Bio Products Laboratory - Biota Pharmaceuticals - Biotest Pharmaceuticals - China Biologic Products - Depomed - Emergent BioSolutions - Ethicon - Flamel Technologies - Kamada - Kedrion - King Pharmaceuticals - Nektar Therapeutics - OMRIX Biopharmaceuticals - ProMetic Life Sciences - Rockwell Medical - The Medicines - ZymoGenetics For more information visit http://www.researchandmarkets.com/research/sk...bal_plasma
CBPO: 97.22 (+2.50), EBS: 30.49 (+0.77), ADMA: 9.37 (+0.12), BOTA: 2.10 (-0.01), ATRS: 1.59 (+0.02), NKTR: 11.34 (+0.56), ABEO: 4.44 (+0.22)
ADMA Biologics wins US patent for RI-002 immune globulin (IG)
M2 - Tue Sep 01, 5:15AM CDT
Biopharmaceutical company ADMA Biologics (NasdaqCM:ADMA) revealed on Monday that it has received the US Patent and Trademark Office's (USPTO) patent titled, 'Compositions And Methods For The Treatment of Immunodeficiency' for RI-002 immune globulin (IG) in treating immune compromised PIDD patients.
ADMA: 9.37 (+0.12)
Respiratory Syncytial Virus (RSV) Infections: Pipeline Review, H1 2015 - Summarizes all the Dormant and Discontinued Pipeline Projects
M2 - Thu Aug 13, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fswgvd/respiratory) has announced the addition of the "Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Respiratory Syncytial Virus (RSV) Infections and enlists all their major and minor projects Companies Mentioned - 3-V Biosciences, Inc. - Ablynx NV - ADMA Biologics, Inc. - Agilvax, Inc. - AlphaVax, Inc. - AmVac AG - Aridis Pharmaceuticals LLC - Artificial Cell Technologies, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Bavarian Nordic A/S - Biota Pharmaceuticals, Inc. - Celltrion, Inc. - Codagenix, Inc. - Crucell N.V. - CureVac GmbH - Emergent BioSolutions Inc. - Evec, Inc. - F. Hoffmann-La Roche Ltd. - GenVec, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Humabs BioMed SA - iBio, Inc. - Immunovaccine, Inc. - Johnson & Johnson - Kineta, Inc. - MedImmune, LLC - Medivir AB - Merck & Co., Inc. - Microbiotix, Inc. - MSM Protein Technologies, Inc. - Mucosis B.V. - NanoBio Corporation For more information visit http://www.researchandmarkets.com/research/fs...espiratory
ADMA: 9.37 (+0.12), EBS: 30.49 (+0.77), BOTA: 2.10 (-0.01), GSK: 40.22 (+0.06), JNJ: 95.37 (+0.29), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), AZN: 32.23 (-0.16), IBIO: 0.68 (unch)
Adma Biologics reports 2Q loss
Automated Insights - Tue Aug 11, 3:57PM CDT
RAMSEY, N.J. (AP) _ Adma Biologics Inc. (ADMA) on Tuesday reported a loss of $4.7 million in its second quarter.
ADMA: 9.37 (+0.12)
ADMA Biologics Reports Second Quarter 2015 Results
GlobeNewswire - Tue Aug 11, 3:38PM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced its financial results for the second quarter ended June 30, 2015, in addition to providing a corporate update and anticipated milestones for 2015.
ADMA: 9.37 (+0.12)
ADMA Biologics submits RI-002's BLA to US FDA for treating patients with PI.
M2 - Mon Aug 03, 4:44AM CDT
Biopharmaceutical company ADMA Biologics (NasdaqCM:ADMA) disclosed on Friday that it has submitted its Biologics License Application (BLA) seeking marketing authorisation for its lead product candidate RI-002 for the treatment of patients with PI. from the US Food and Drug Administration (FDA).
ADMA: 9.37 (+0.12)
ADMA Biologics Announces Submission of RI-002 Biologics License Application (BLA) to FDA
GlobeNewswire - Fri Jul 31, 8:28AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the primary immunodeficiency (PI) population and the treatment and prevention of certain infectious diseases, announced that it has submitted its Biologics License Application (BLA) to the United States Food and Drug Administration (FDA), seeking marketing authorization for RI-002.
ADMA: 9.37 (+0.12)
ADMA Biologics Announces Recent Commercialization Focused Appointments
GlobeNewswire - Mon Jul 06, 6:38AM CDT
Senior Vice President of Commercialization & Strategy
ADMA: 9.37 (+0.12)
ADMA Biologics Shares Possibly Worth A Triple On FDA Approval Of RI-002
Jason Napodano, CFA - at Seeking Alpha - Tue Jun 30, 9:18AM CDT
ADMA: 9.37 (+0.12)
ADMA Biologics Receives Notice of Allowance for U.S. Patent Pertaining to Its Lead Product Candidate RI-002
GlobeNewswire - Tue Jun 30, 6:08AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company, announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application 14/592,721 entitled Compositions and Methods For The Treatment of Immunodeficiency.
ADMA: 9.37 (+0.12)
ADMA Biologics Joins Russell Microcap(R) Index
GlobeNewswire - Mon Jun 29, 6:38AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company developing specialty plasma-based biologics for the primary immunodeficiency (PI) population and the treatment and prevention of certain infectious diseases, announced that it was added to the Russell Microcap(R) Index. The newly reconstituted indexes took effect following market close on June 26, 2015.
ADMA: 9.37 (+0.12)
ADMA Biologics to Present at the 2015 JMP Securities Life Sciences Conference
GlobeNewswire - Tue Jun 16, 6:38AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it will present at the 2015 JMP Securities Life Sciences Conference on June 24, 2015 in New York City at The St. Regis New York.
ADMA: 9.37 (+0.12)
ADMA Biologics & Jeffrey Modell Foundation Initiate Strategic Patient Advocacy Alliance
GlobeNewswire - Thu Jun 11, 6:38AM CDT
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company developing specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it has initiated a collaboration with the Jeffrey Modell Foundation (JMF), a global nonprofit organization dedicated to patients with Primary Immunodeficiencies (PI). There are more than 250 genetic defects that are classified under the PI umbrella. The National Institutes of Health (NIH) estimates that at least 500,000 Americans are affected, many of whom are undiagnosed. JMF programs focus on early diagnosis and meaningful treatments through research, physician and patient education, public awareness, government advocacy, patient support and newborn screening.
ADMA: 9.37 (+0.12)